Jack Kessler Sample Contracts

SEC Documents
Filings
Personal financials
Insider transactions
Previous Companies
director until January 3rd, 2011
Symbollon Corp – TERMINATION OF AMENDED AND RESTATED EMPLOYMENT AGREEMENT (May 19th, 2008)

This Termination, dated as of the 16th day of May, 2008, of the Amended and Restated Employment Agreement dated as of January 3, 2006, as amended on February 7, 2008 (the “Agreement”), by and between Symbollon Pharmaceuticals, Inc., a Delaware corporation with its principal place of business at 37 Loring Drive, Framingham, MA  01702 (the "Company"), and Jack H. Kessler, residing at 56 Presidential Drive, Southborough, MA  01772 (the "Employee").  Capitalized terms used but not defined herein shall have the meaning as defined in the Agreement.  Except as amended below, all terms and conditions of the Agreement shall remain in full force and effect.

Symbollon Corp – AMENDED AND RESTATED EMPLOYMENT AGREEMENT (January 6th, 2006)

This Employment Agreement is made as of the 3rd day of January, 2006, by and between Symbollon Pharmaceuticals, Inc., a Delaware corporation with its principal place of business at 37 Loring Drive, Framingham, MA 01702 (the "Company"), and Jack H. Kessler, residing at 56 Presidential Drive, Southborough, MA 01772 (the "Employee").

Symbollon Corp – SYMBOLLON ANNOUNCES RESIGNATIONS OF EXECUTIVE OFFICERS OVER CONTRACT ISSUES Company intends to rehire executives at the start of New Year (January 6th, 2006)

This news release contains statements by the Company that involve risks and uncertainties and may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements reflect management’s current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including, but not limited to, the risks and uncertainties associated with whether (i) future clinical trial results will support the use of IoGen for the treatment of fibrocystic breast disease, (ii) the clinical data acquired from Mimetix Inc. will be acceptable exposure data for IoGen, (iii) Symbollon will be able to obtain the resources necessary to continue as a going concern, (iv) IoGen will successfully complete the regulatory approval process, (v) competitive products will receive regulat

Symbollon Corp – PRESS RELEASE SYMBOLLON PHARMACEUTICALS, INC. 37 Loring Drive, Framingham, MA 01702 Phone: (508) 620-7676 Fax: (508) 620-7111 FOR IMMEDIATE RELEASE SYMBOLLON FINALIZES MIMETIX ASSET ACQUISITION Acquisition Modified to Include the Mimetix Intellectual Property COMPANY CONTACT: Paul C. Desjourdy, President Symbollon Pharmaceuticals, Inc. (508) 620-7676, x202 www.symbollon.com INVESTOR CONTACT: Barry Kaplan, President Barry Kaplan Associates (732) 747-0702 smallkap@aol.com FRAMINGHAM, MASSACHUSETTS, Monday, June 14, 2004 -- Symbollon Pharmaceuticals, Inc. (OTCBB: SYMBA) today announced that it ha (July 2nd, 2004)
Symbollon Corp – PRESS RELEASE SYMBOLLON PHARMACEUTICALS, INC. 37 Loring Drive, Framingham, MA 01702 Phone: (508) 620-7676 Fax: (508) 620-7111 FOR IMMEDIATE RELEASE SYMBOLLON ACQUIRES PATIENT CLINICAL DATA OF MIMETIX Acquisition of Patient Data is Estimated to Cut IoGen Drug Development in Half COMPANY CONTACT: Paul C. Desjourdy, President Symbollon Pharmaceuticals, Inc. (508) 620-7676, x202 www.symbollon.com INVESTOR CONTACT: Barry Kaplan, President Barry Kaplan Associates (732) 747-0702 smallkap@aol.com FRAMINGHAM, MASSACHUSETTS, Wednesday, April 7, 2004 -- Symbollon Pharmaceuticals, Inc. (OTCBB: SYMBA) toda (April 9th, 2004)
Symbollon Corp – SYMBOLLON PHARMACEUTICALS, INC. 37 Loring Drive, Framingham, MA 01702 Phone: (508) 620-7676 Fax: (508) 620-7111 FOR IMMEDIATE RELEASE SYMBOLLON PHARMACEUTICALS, INC. ANNOUNCES THIRD QUARTER 2002 RESULTS COMPANY FACES POSSIBLE NASDAQ DELISTING CONTACT: Paul C. Desjourdy, President/COO SYMBOLLON PHARMACEUTICALS, INC. (508) 620-7676, x202 FRAMINGHAM, MASSACHUSETTS, November 14, 2002 -- Symbollon Pharmaceuticals, Inc. (NASDAQ: SYMBA) today announced a net loss for the quarter ended September 30, 2002. For the three months ended September 30, 2002, the Company reported a net loss of $130,760, or a (November 14th, 2002)

Three Months Ended Nine Months Ended September 30, September 30, ----------------------------------- --------------------------------- 2002 2001 2002 2001 ------------- -------------- ------------- ------------ Revenue: Net Product Sales $ 76 $ 51 $ 280 $ 156 Contract Revenues --- --- --- 5 License Fee Revenues --- --- --- ---

Symbollon Corp – FOR IMMEDIATE RELEASE SYMBOLLON RAISES $1.8 MILLION THROUGH WARRANT EXERCISE Contacts: Symbollon: Paul C. Desjourdy Investors: Tim Curtiss President/COO Wall Street Investor Relations (508) 620-7676, x12 (877) 925-5784 FRAMINGHAM, MASSACHUSETTS, September 11, 2000 -- Symbollon Corporation (NASDAQ:SYMBA) today announced that it has received $1.8 million from the exercise of outstanding warrants. "We are pleased to report that 586,910 warrants were voluntarily exercised by their holders at $3.00 per share," stated Paul C. Desjourdy, President and COO of Symbollon. "With this new capital, the Com (September 11th, 2000)
Symbollon Corp – FOR IMMEDIATE RELEASE SYMBOLLON ANNOUNCES FAVORABLE PHASE II TRIAL RESULTS FOR IOGEN Contacts: Symbollon: Paul C. Desjourdy Investors: Tim Curtiss President/COO Wall Street Investor Relations (508) 620-7676, x12 (877) 925-5784 FRAMINGHAM, MASSACHUSETTS, August 16, 2000 -- Symbollon Corporation (NASDAQ:SYMBA) today announced favorable preliminary results of a Phase II clinical trial for its patented drug, IoGen(TM). IoGen is being developed as a treatment for fibrocystic breast disease (FBD). "The objective of our Phase II trial was to investigate IoGen's safety and efficacy at various dosage l (August 18th, 2000)
Symbollon Corp – AMENDED AND RESTATED EMPLOYMENT AGREEMENT (March 27th, 2000)
Symbollon Corp – STOCK PURCHASE AGREEMENT (November 6th, 1996)